Methicillin-resistant Staphylococcus Aureus Drugs Market Size & Share, by Drug Class (Lipopeptide, Oxazolidine, Tetracycline, Cephalosporin, Lipoglycopeptide, Folate Antagonist); Administration (Oral, Parenteral); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5531
  • Published Date: Jan 15, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Methicillin-resistant Staphylococcus Aureus Drugs Market size is projected to cross USD 9 Billion by the end of 2036, growing at a CAGR of over 5% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of methicillin-resistant staphylococcus aureus drugs was about USD 4 Billion. The growth of the market is poised to be dominated by the growing prevalence of MRSA infection. A total of 119 studies with 164,717 participants from 29 different nations were determined to be suitable for meta-analysis. The meta-analysis showed that in the world, MRSA was present in 14.69% of cases. Therefore, the demand for medication for this infection is growing which is further estimated to boost this market.

Furthermore, the most prevalent kind of staphylococcus infections involve those that affect the skin and soft tissues. The frequency of skin and soft tissue infections has increased as a result of an increasing number of antimicrobial medication failure in outpatient treatment. Thus, one of the main factors influencing market growth throughout the projected period is the increased prevalence of staphylococcal infections.


Methicillin Resistant Staphylococcus Aureus Market
Get more information on this report: Request Free Sample PDF


Methicillin-resistant Staphylococcus Aureus Drugs Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~5%

Base Year Market Size (2023)

~ USD 4 Billion

Forecast Year Market Size (2036)

~ USD 9 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Methicillin-resistant Staphylococcus Aureus Drugs Sector: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Surge in Geriatric Population - One in six individuals on the entire globe is predicted to be 60 years of age or beyond by 2030. At this point, there are predicted to be 1.4 billion people over the age of 60, up from 1 billion in 2020. Hence, with this the cases of MRSA in also growing in older people. Since MRSA is resistant to common antibiotics, it poses a significant risk to elderly people owing to the high intake of antibiotics. This is high, particularly in institutional settings where seniors are already at a higher risk of mortality from the illness.  Furthermore, the immune of older people is also weak which makes them highly prone to this infection.
  • Rising Adoption of AI in Healthcare - AI is proving its importance in the healthcare sector. For instance, through the application of deep learning, a form of artificial intelligence, MIT researchers have identified a class of drugs capable of eliminating a drug-resistant bacterium that accounts for over 9,000 fatalities annually in the US. Hence, the use of AI has also shown great accuracy in screening tests for MRSA. A particular screening test is frequently used to detect patients who possess MRSA. Clinicians may find it useful to use MRSA detection to identify individuals who may potentially spread the infection to other patients as well as to choose the best medicines. However, real-time information is unable to be obtained using the widely utilized culture screening method for MRSA since it takes several days to receive the result. Therefore, it would be extremely important and impactful in the clinical situation to accurately and promptly predict whether MRSA is present in patients on mechanical ventilation. Machine learning techniques are beneficial for clinical decision assistance in infectious diseases.
  • Rise in Product Approval - Public health protection is the primary goal of drug and medical device regulatory agencies worldwide. Their choices have the power to genuinely generate or destroy market opportunities. In addition, they are becoming more and more crucial in fostering an environment that supports innovation in healthcare. As a result, there has been a surge in approval of various medications and technology which is further estimated to influence the methicillin-resistant staphylococcus aureus drugs market expansion.

Challenges

  • Lack of Trained Professional in the Field of MRSA Testing - Accurate interpretation of findings is necessary for MRSA testing procedures, and researchers need to understand which analyses to perform and how to connect them to the experiment's main goal. Therefore, an adequate understanding of the relevant technology is necessary for the researcher to conduct successful research experiments. As such, the MRSA identification procedure needs to be carried out by highly qualified individuals. The majority of lab professionals lack sufficient training regarding the newest innovations in lab equipment and their advantages. Furthermore, there is a dearth of skilled workers capable of operating highly developed diagnostic equipment.
  • High Cost of Testing
  • Lack of Awareness About MRSA Infection


Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

The hospital pharmacy segment in the methicillin-resistant staphylococcus aureus drugs market is set to capture the largest share of over 50% during the forecast period. This could be owing to the rising number of hospitals in this region. The total number of hospitals around the globe as of 2021 is projected to be about 164,000. Furthermore, hospitals are the exclusive partners with hospital-based reference laboratories for MRSA testing. Due to the huge volume of patients, lengthy turnaround times, and high costs associated with hospitals, only a small number of complex tests are referred to these laboratories. These labs use skilled laboratory professionals and state-of-the-art equipment to handle the large volume of tests. Clinical research, disease surveillance programs, monitoring response to treatment, and disease diagnosis all depend significantly on hospitals and diagnostic labs. Timely and timely intervention is made feasible by diagnostic techniques, which lowers the impact of disease and improves health. The medication needed for MRSA is determined using the information gathered from patient samples.

Our in-depth analysis of the global methicillin-resistant staphylococcus aureus drugs market includes the following segments:

     Drug Class

  • Lipopeptide
  • Oxazolidine
  • Tetracycline
  • Cephalosporin
  • Lipoglycopeptide
  • Folate Antagonist

     Administration

  • Oral
  • Parenteral

     Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Methicillin-resistant Staphylococcus Aureus Drugs Industry - Regional Synopsis

North American Market Forecast

The North America methicillin-resistant staphylococcus aureus drugs market is projected to gather the largest revenue share of over 40% during the coming years. This growth is set to be influenced by rising COVID-19 cases. At this point in Northern America, the new coronavirus has been responsible for at least over 93,186,000 recorded infections and about 1,065,000 documented deaths. Multiple manufacturing facilities in the United States were forced to close as a consequence of the COVID-19 outbreak.  Nonetheless, since COVID-19 patients require more stringent hygienic measures, the outbreak assisted in the local MRSA testing business expand. MRSA testing suppliers have to boost production in response to the pandemic to keep up with the rising demand. This is in addition to the fact that one of the regions in the market under study with the quickest growth is North America. Additionally, throughout the projected period, the United States is projected to dominate the global MRSA treatment market. The primary source of this share of the market is the funding provided by American businesses for the investigation and creation of instruments for evaluating MRSA infection.

European Market Analysis

The methicillin-resistant staphylococcus aureus drugs market in Europe is also estimated to have notable growth over the forecast period. To reduce the prevalence of surgical site infections (SSIs) in the country, the UK government has initiated major action. One of the most prevalent types of infections connected with hospital settings is surgical site infection (SSI) (HAIs). SSIs are linked to increased attributable morbidity and mortality, longer hospital admissions following surgery, the need for further surgical procedures, and the need for critical care. The Europe market for methicillin-resistant staphylococcus aureus (MRSA) is experiencing expansion as a result of the government's increased efforts and preventive measures to control surgical site infections.

Research Nester
Methicillin Resistant Staphylococcus Aureus Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Methicillin-resistant Staphylococcus Aureus Drugs Landscape

top-features-companies
    • BD (Becton, Dickinson and Company)
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Melinta Therapeutics LLC
    • Dr. Reddy’s Laboratories Ltd.
    • Cardinal Health
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Baxter
    • Crown Laboratories, Inc.
    • Atlantic Biologicals
    • Apollo Health Care Corporation Inc. 

In-the-news

In The News

  • Leading international medical technology company BD (Becton, Dickinson and Company) announced receiving FDA 510(k) clearance for its new BD Kiestra Methicillin-resistant Staphylococcus aureus (MRSA) imaging application. The application leverages artificial intelligence (AI) to interpret bacterial growth and release negative specimens with minimal human intervention.
  • Melinta Therapeutics (Melinta) is a commercial-stage company that develops novel treatments for acute and life-threatening illnesses. The company recently announced the commercial launch of KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that treats acute bacterial skin and skin structure infections (ABSSSI) completely with a single 1,200 mg infusion that takes one hour. On March 12, 2021, the U.S. Food and Drug Administration approved KIMYRSA for the treatment of adult patients with ABSSSI brought on by susceptible isolates of specific Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA).   

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5531
  • Published Date: Jan 15, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are surge in geriatric population, rising adoption of AI in healthcare, and rise in product approval.

The market size of methicillin-resistant staphylococcus aureus drugs is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2024 – 2036.

The major players in the market are BD (Becton, Dickinson and Company), Melinta Therapeutics LLC, Dr. Reddy’s Laboratories Ltd., Cardinal Health, and others.

The hospital pharmacy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Methicillin-resistant Staphylococcus Aureus Drugs Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying